Clinical Trials Logo

EGFR and/or ROS Mutant NSCLC clinical trials

View clinical trials related to EGFR and/or ROS Mutant NSCLC.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01219543 Terminated - Gastric Cancer Clinical Trials

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Start date: November 2010
Phase: Phase 1
Study type: Interventional

This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in the escalation phase, EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer in the expansion phase and to evaluate daily and BID dosing.